目前的药物靶点(Current Drug Targets)是一本由Bentham Science Publishers B.V.出版的一本医学-药学学术刊物,主要报道医学-药学相关领域研究成果与实践。本刊已入选来源期刊,该刊创刊于2000年,出版周期Bimonthly。2021-2022年最新版WOS分区等级:Q2,2023年发布的影响因子为3,CiteScore指数6.2,SJR指数0.691。本刊非开放...
影响因子(2023) 2.664Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes an...
当前的抗癌药物靶点(Current Cancer Drug Targets)是一本由Bentham Science Publishers B.V.出版的一本医学-肿瘤学学术刊物,主要报道医学-肿瘤学相关领域研究成果与实践。本刊已入选来源期刊,该刊创刊于2001年,出版周期Bimonthly。2021-2022年最新版WOS分区等级:Q3,2023年发布的影响因子为2.3,CiteScore指数5.4,SJR指数...
External Cites per document 2023 1.940 Cites per document 2008 0.000 Cites per document 2009 0.943 Cites per document 2010 2.984 Cites per document 2011 3.101 Cites per document 2012 3.356 Cites per document 2013 3.364 Cites per document 2014 4.034 Cites per document 2015 2.079 Cites per document...
Endocrine-disrupting chemicals (EDCs) are a heterogeneous group of natural and man-made chemicals from environmental sources that mimic natural hormones. T
2015-2023 Information Homepage Scope Current Pharmacology Reports will: publish cutting-edge reviews on subjects pertinent to all aspects of pharmacology, including drug discovery and development, provide incisive, insightful, and balanced contributions from international leading experts, interest a wide reade...
Gallbladder cancer (GBC) is rare, but is the most malignant type of biliary tract tumor. Unfortunately, only a small population of cancer patients is acceptable for the surgical resection, the current effective regimen; thus, the high mortality rate has
Journal of Ovarian Research volume 16, Article number: 6 (2023) Cite this article 11k Accesses 1 Altmetric Metrics details Abstract As a kind of gynecological tumor, ovarian cancer is not as common as cervical cancer and breast cancer, but its malignant degree is higher. Despite the ...
Lancet https://doi.org/10.1016/S0140-6736(22)01841-4 (2023). The first large-scale prospective randomized study to show that a panel pharmacogenomics approach can reduce adverse drug reactions. Relling, M. V. et al. The Clinical Pharmacogenetics Implementation Consortium: 10 years later. Clin....
targets. Here we discuss in detail three critical pathways, Janus kinase/signal transducer and activator of transcription (JAK/STAT), Th17, and hypoxia-inducible factor (HIF), and their roles as unique therapeutic targets in the field of RA. Some of the less developed but potential targets ...